PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20216312-1 2010 PURPOSE OF REVIEW: Inhibition of sphingolipid synthesis increases insulin sensitivity, resolves hepatic steatosis, and prevents the onset of diabetes in obese rodents. Sphingolipids 33-45 insulin Homo sapiens 66-73 20216312-8 2010 Why: sphingolipids have an evolutionarily conserved role to starve cells of nutrients, and the inhibition of insulin action is possibly a component of this broader action. Sphingolipids 5-18 insulin Homo sapiens 109-116 18548166-0 2008 The role of skeletal muscle sphingolipids in the development of insulin resistance. Sphingolipids 28-41 insulin Homo sapiens 64-71 19833891-1 2010 OBJECTIVE: We tested the primary hypotheses that sphingolipid and diacylglycerol (DAG) content is higher within insulin-resistant muscle and that the association between intramyocellular triglycerides (IMTG) and insulin resistance is muscle fiber type specific. Sphingolipids 49-61 insulin Homo sapiens 112-119 19303901-3 2009 Ceramide, the most simple sphingolipid, directly inhibits phosphorylation of the insulin signaling mediator Akt/Protein Kinase B. Sphingolipids 26-38 insulin Homo sapiens 81-88 18397976-2 2008 Intramyocellular sphingolipids (i.e. ceramide) have been suggested to induce insulin resistance by interfering with the insulin signaling cascade in obesity. Sphingolipids 17-30 insulin Homo sapiens 77-84 18397976-2 2008 Intramyocellular sphingolipids (i.e. ceramide) have been suggested to induce insulin resistance by interfering with the insulin signaling cascade in obesity. Sphingolipids 17-30 insulin Homo sapiens 120-127 18451260-4 2008 Moreover, studies in cultured cells and isolated tissues implicate sphingolipids in certain cellular events associated with diabetes and cardiovascular disease, including insulin resistance, pancreatic beta-cell failure, cardiomyopathy, and vascular dysfunction. Sphingolipids 67-80 insulin Homo sapiens 171-178 18451260-5 2008 However, definitive evidence that sphingolipids contribute to insulin resistance, diabetes, and atherosclerosis has come only recently, as researchers have found that pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates each of these conditions. Sphingolipids 34-47 insulin Homo sapiens 62-69 18451260-5 2008 However, definitive evidence that sphingolipids contribute to insulin resistance, diabetes, and atherosclerosis has come only recently, as researchers have found that pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates each of these conditions. Sphingolipids 34-46 insulin Homo sapiens 62-69 18451260-6 2008 Herein we will review the role of ceramide and other sphingolipid metabolites in insulin resistance, beta-cell failure, cardiomyopathy, and vascular dysfunction, focusing on these in vivo studies that identify enzymes controlling sphingolipid metabolism as therapeutic targets for combating metabolic disease. Sphingolipids 53-65 insulin Homo sapiens 81-88 34954721-4 2022 Ceramides, such as sphingolipids are also produced intracellularly and have signalling actions in regulating cell metabolism including effects on inflammation, and potentially have a mechanistic role in the development of insulin resistance. Sphingolipids 19-32 insulin Homo sapiens 222-229 11424085-6 2001 Pretreatment of insulin, a potent stimulator of AKT kinase, partially reversed the inhibition of AKT kinase by sphingosine and counteracted the apoptotic action of this sphingolipid. Sphingolipids 169-181 insulin Homo sapiens 16-23 1651108-2 1991 This lysosphingolipid has been shown previously to inhibit the Ca2+/lipid-dependent protein kinase C. Here we show that insulin-dependent autophosphorylation of partially purified insulin receptor is half-maximally inhibited by 145 microM sphingosine (9 mol %) in Triton X-100 micelles. Sphingolipids 5-21 insulin Homo sapiens 120-127 33815291-0 2021 Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes. Sphingolipids 0-13 insulin Homo sapiens 59-66 33815291-4 2021 A significant number of studies have described the involvement of ceramides and other sphingolipids in the inhibition of insulin-signaling pathway in both skeletal muscles and the liver. Sphingolipids 86-99 insulin Homo sapiens 121-128 33815291-6 2021 Sphingolipids, in addition to their direct impact on the insulin signaling pathway, may be responsible for other negative aspects of diabetes, namely mitochondrial dysfunction and deficiency. Sphingolipids 0-13 insulin Homo sapiens 57-64 33815291-13 2021 In this review, we focus on the current state of scientific knowledge regarding the involvement of sphingolipids in the induction of insulin resistance by inhibiting mitochondrial function. Sphingolipids 99-112 insulin Homo sapiens 133-140 34962430-0 2022 Insulin regulates Nedd4-2 via a PKB-dependent mechanism in HEI-OC1 auditory cells-crosstalks with sphingolipid and cAMP signaling. Sphingolipids 98-110 insulin Homo sapiens 0-7 17339025-5 2007 First, they indicate that different fatty acids induce insulin resistance by distinct mechanisms discerned by their reliance on sphingolipid synthesis. Sphingolipids 128-140 insulin Homo sapiens 55-62 15774472-9 2005 Moreover, these FFAs stimulated the de novo synthesis of ceramide and sphingosine, two sphingolipids shown previously to inhibit insulin action. Sphingolipids 87-100 insulin Homo sapiens 129-136 15671480-1 2005 The potential contribution of lipids to insulin signaling has excited interest because of the notion that cholesterol and sphingolipids form functional microdomains-lipid rafts-in cell membranes and that these domains may affect signal transduction. Sphingolipids 122-135 insulin Homo sapiens 40-47 15671480-2 2005 In this Perspective, we discuss the evidence suggesting that cholesterol-sphingolipid rafts play a role in the pathogenesis of insulin resistance. Sphingolipids 73-85 insulin Homo sapiens 127-134 34204938-11 2021 Furthermore, increased concentration of sphingolipids, mainly sphinganine, inhibited insulin pathway proteins phosphorylation, increasing insulin resistance development. Sphingolipids 40-53 insulin Homo sapiens 85-92 34204938-11 2021 Furthermore, increased concentration of sphingolipids, mainly sphinganine, inhibited insulin pathway proteins phosphorylation, increasing insulin resistance development. Sphingolipids 40-53 insulin Homo sapiens 138-145 35584813-4 2022 Sphingolipids such as ceramides are among the most deleterious and bioactive metabolites that accrue, as they participate in selective insulin resistance, dyslipidemia, oxidative stress and apoptosis. Sphingolipids 0-13 insulin Homo sapiens 135-142 34204938-1 2021 The aim of the study was to evaluate the influence of vitamin K2 (VK2) supplementation on the sphingolipid metabolism pathway in palmitate-induced insulin resistant hepatocytes. Sphingolipids 94-106 insulin Homo sapiens 147-154 33504931-10 2021 CONCLUSIONS: Prenatal exposure to maternal higher adiposity and hyperglycemic traits and lower insulin sensitivity markers were associated with a unique metabolomic pattern characterized by low serum phospho- and sphingolipids in mid-childhood. Sphingolipids 213-226 insulin Homo sapiens 95-102 35406045-3 2022 Ceramides are bioactive sphingolipids whose dysregulated metabolism contribute to lipotoxicity, insulin resistance, and CMR. Sphingolipids 24-37 insulin Homo sapiens 96-103 3527163-0 1986 Sphingolipids inhibit insulin and phorbol ester stimulated uptake of 2-deoxyglucose. Sphingolipids 0-13 insulin Homo sapiens 22-29 35054078-8 2022 Sphingolipids are known to be a modulator of insulin resistance, and our results indicate that ceramide measurements in early pregnancy may help with GDM screening. Sphingolipids 0-13 insulin Homo sapiens 45-52 33738905-1 2021 Sphingolipids, in particular ceramides, play vital role in pathophysiological processes linked to metabolic syndrome, with implications in the development of insulin resistance, pancreatic ss-cell dysfunction, type 2 diabetes, atherosclerosis, inflammation, nonalcoholic steatohepatitis, and cancer. Sphingolipids 0-13 insulin Homo sapiens 158-165 33592213-8 2021 CONCLUSIONS: These results provide novel associations between serum sphingolipid between insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp and identify two specific SPs that may represent prognostic biomarkers for insulin sensitivity. Sphingolipids 68-80 insulin Homo sapiens 89-96 33592213-8 2021 CONCLUSIONS: These results provide novel associations between serum sphingolipid between insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp and identify two specific SPs that may represent prognostic biomarkers for insulin sensitivity. Sphingolipids 68-80 insulin Homo sapiens 130-137 33296380-1 2020 BACKGROUND: Animal studies suggest vital roles of sphingolipids, especially ceramides, in the pathogenesis of type 2 diabetes (T2D) via pathways involved in insulin resistance, beta-cell dysfunction, and inflammation, but human studies are limited. Sphingolipids 50-63 insulin Homo sapiens 157-164 33158378-3 2021 Among the numerous lipid subtypes that accumulate, sphingolipids such as ceramides are particularly impactful, as they elicit the selective insulin resistance, dyslipidemia, and ultimately cell death that underlie nearly all metabolic disorders. Sphingolipids 51-64 insulin Homo sapiens 140-147 33592213-0 2021 Targeted lipidomics reveals associations between serum sphingolipids and insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp. Sphingolipids 55-68 insulin Homo sapiens 73-80 33592213-2 2021 This study aimed to systematically investigate the associations between serum sphingolipids and insulin sensitivity as well as insulin secretion. Sphingolipids 78-91 insulin Homo sapiens 96-103 33128577-1 2021 AIMS/HYPOTHESIS: Subcellular localisation is an important factor in the known impact of bioactive lipids, such as diacylglycerol and sphingolipids, on insulin sensitivity in skeletal muscle; yet, the role of localised intramuscular triacylglycerol (IMTG) is yet to be described. Sphingolipids 133-146 insulin Homo sapiens 151-158 31150623-3 2019 Here we demonstrate that the C16:0 sphingolipid synthesizing ceramide synthases, CerS5 and CerS6, affect distinct sphingolipid pools and that abrogation of CerS6 but not of CerS5 protects from obesity and insulin resistance. Sphingolipids 35-47 insulin Homo sapiens 205-212 31545927-5 2019 This review summarizes the novel knowledge that intracellular lipids such as cholesterol and sphingolipids are major determinants of podocyte insulin signaling. Sphingolipids 93-106 insulin Homo sapiens 142-149 32424203-2 2020 Ceramides, a type of sphingolipid (SL), have been implicated in the development of a range of metabolic disorders from insulin resistance (IR) to hepatic steatosis. Sphingolipids 21-33 insulin Homo sapiens 119-126 32424203-2 2020 Ceramides, a type of sphingolipid (SL), have been implicated in the development of a range of metabolic disorders from insulin resistance (IR) to hepatic steatosis. Sphingolipids 35-37 insulin Homo sapiens 119-126 32098447-2 2020 A substantial body of evidence has implicated ceramides, a sphingolipid intermediate, as potent antagonists of insulin action that drive insulin resistance. Sphingolipids 59-71 insulin Homo sapiens 111-118 29485983-5 2018 Wearable-derived activity levels can be used to identify known and novel activity-modulated sphingolipids that are in turn associated with insulin sensitivity. Sphingolipids 92-105 insulin Homo sapiens 139-146 30586632-8 2019 Dihydroceramide, a sphingolipid precursor, was independently and negatively correlated with insulin sensitivity (beta [95% CI] = -1.9 [-2.9, -0.9], p = 0.01), indicating a possible upregulation in sphingolipid synthesis in obese individuals. Sphingolipids 19-31 insulin Homo sapiens 92-99 30586632-8 2019 Dihydroceramide, a sphingolipid precursor, was independently and negatively correlated with insulin sensitivity (beta [95% CI] = -1.9 [-2.9, -0.9], p = 0.01), indicating a possible upregulation in sphingolipid synthesis in obese individuals. Sphingolipids 197-209 insulin Homo sapiens 92-99 30594552-12 2019 These findings compliment previous research, which linked these sphingolipids with fasting insulin levels, and suggest that higher levels of these ceramides and lower LC-16 may be an early marker of impaired glucose metabolism. Sphingolipids 64-77 insulin Homo sapiens 91-98 30630661-1 2019 OBJECTIVE: Sphingolipids have a fundamental role in many cellular processes, and they have been implicated in insulin resistance and Diabetes Mellitus (DM) and its complications, including diabetic retinopathy (DR). Sphingolipids 11-24 insulin Homo sapiens 110-117 30468835-1 2019 AIMS: Obesity and type 2 diabetes mellitus, correlate with increased tissue concentration of sphingolipids, which directly interfere with insulin signaling pathway. Sphingolipids 93-106 insulin Homo sapiens 138-145 30473005-6 2018 The processes of adipogenesis, metabolism and thermogenesis, in addition to inflammation and insulin resistance are intimately linked to sphingolipids as discussed below. Sphingolipids 137-150 insulin Homo sapiens 93-100 30159588-1 2018 AIMS/HYPOTHESIS: Ceramides are sphingolipids that contribute to insulin resistance in preclinical studies. Sphingolipids 31-44 insulin Homo sapiens 64-71 29602794-0 2018 Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis. Sphingolipids 17-30 insulin Homo sapiens 41-48 29602794-10 2018 CONCLUSIONS: Sphingolipid species are not only increased in insulin-resistant humans with NASH but also correlate with hepatic oxidative stress and inflammation, suggesting that these lipids may play a role during progression of simple steatosis to NASH in humans. Sphingolipids 13-25 insulin Homo sapiens 60-67 30645667-14 2019 Attenuating sphingolipid metabolism in islets impairs glucose-stimulated insulin secretion. Sphingolipids 12-24 insulin Homo sapiens 73-80 29588286-2 2018 However, the relationships of circulating ceramides and related sphingolipids with plasma insulin have been underexplored in humans. Sphingolipids 64-77 insulin Homo sapiens 90-97 29588286-4 2018 We examined sphingolipid associations with both baseline and follow-up measures of plasma insulin, HOMA of insulin resistance (HOMA-IR), and HOMA of beta-cell function (HOMA-B) after adjustment for risk factors. Sphingolipids 12-24 insulin Homo sapiens 90-97 29588286-4 2018 We examined sphingolipid associations with both baseline and follow-up measures of plasma insulin, HOMA of insulin resistance (HOMA-IR), and HOMA of beta-cell function (HOMA-B) after adjustment for risk factors. Sphingolipids 12-24 insulin Homo sapiens 107-114 29767564-6 2018 Intracellular lipids such as diacylglycerols and sphingolipids can serve as lipotoxins by directly inhibiting insulin action in muscle and liver. Sphingolipids 49-62 insulin Homo sapiens 110-117 28462811-3 2017 Here we discuss various sphingolipid transport mechanisms and highlight how changes in cellular and plasma sphingolipid levels contribute to cardiovascular disease, obesity, diabetes, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). Sphingolipids 107-119 insulin Homo sapiens 184-191 29415895-0 2018 Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle. Sphingolipids 50-63 insulin Homo sapiens 75-82 29415895-12 2018 CONCLUSION: These data reveal previously unknown differences in subcellular localization of skeletal muscle DAGs and sphingolipids that relate to whole-body insulin sensitivity and mitochondrial function in humans. Sphingolipids 117-130 insulin Homo sapiens 157-164 28714882-12 2017 The regulation of sphingolipid signaling by vitamin D may thus unravel a novel mechanism by which vitamin D can influence glucose utilization and insulin action. Sphingolipids 18-30 insulin Homo sapiens 146-153 29186855-3 2017 In addition to being involved in dynamic cellular processes like apoptosis, senescence and differentiation, sphingolipids are implicated in critical physiological functions such as immune responses and pathophysiological conditions like inflammation and insulin resistance. Sphingolipids 108-121 insulin Homo sapiens 254-261 26739815-0 2016 Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Sphingolipids 7-20 insulin Homo sapiens 69-76 27940403-1 2017 BACKGROUND AND AIMS: Plasma sphingolipids including ceramides, and gangliosides are associated with insulin resistance (IR) through effects on insulin signalling and glucose metabolism. Sphingolipids 28-41 insulin Homo sapiens 100-107 27940403-1 2017 BACKGROUND AND AIMS: Plasma sphingolipids including ceramides, and gangliosides are associated with insulin resistance (IR) through effects on insulin signalling and glucose metabolism. Sphingolipids 28-41 insulin Homo sapiens 143-150 26739815-1 2016 AIMS/HYPOTHESES: Ceramides and other sphingolipids comprise a family of lipid molecules that accumulate in skeletal muscle and promote insulin resistance. Sphingolipids 37-50 insulin Homo sapiens 135-142 26739815-8 2016 CONCLUSIONS/INTERPRETATION: These data suggest ceramide and other sphingolipids containing stearate (18:0) are uniquely related to insulin resistance in skeletal muscle. Sphingolipids 66-79 insulin Homo sapiens 131-138 26412155-2 2015 Of the myriad lipids that accrue under these conditions, sphingolipids such as ceramide or its metabolites are amongst the most deleterious because they disrupt insulin sensitivity, pancreatic beta cell function, vascular reactivity, and mitochondrial metabolism. Sphingolipids 57-70 insulin Homo sapiens 161-168 26916476-8 2016 RESULTS: In muscle, insulin resistance was characterized by higher levels of C18:0 sphingolipids, while in plasma, higher levels of diacylglycerol and cholesterol ester, and lower levels of lysophosphatidylcholine and lysoalkylphosphatidylcholine, indicated insulin resistance, irrespective of overweight/obesity. Sphingolipids 83-96 insulin Homo sapiens 20-27 26916476-9 2016 The sphingolipid metabolism gene pathway was upregulated in muscle in insulin resistance independent of obesity. Sphingolipids 4-16 insulin Homo sapiens 70-77 26916476-11 2016 CONCLUSIONS: Muscle C18:0 sphingolipids may play a role in insulin resistance independent of excess adiposity. Sphingolipids 26-39 insulin Homo sapiens 59-66 26350457-2 2015 Aberrant plasma levels of sphingolipids contribute to metabolic disease, atherosclerosis, and insulin resistance. Sphingolipids 26-39 insulin Homo sapiens 94-101 25623782-2 2015 There is increasing evidence that sphingolipids play a role in insulin resistance and type 2 diabetes (T2DM). Sphingolipids 34-47 insulin Homo sapiens 63-70 26126684-0 2015 Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Sphingolipids 6-19 insulin Homo sapiens 38-45 26126684-1 2015 Ceramides and sphingolipids are a family of lipid molecules that circulate in serum and accumulate in skeletal muscle, promoting insulin resistance. Sphingolipids 14-27 insulin Homo sapiens 129-136 24379346-9 2014 The results revealed that 1-deoxysphinganine is a cytotoxic lipid for insulin-producing cells, suggesting that the increased levels of this sphingolipid observed in diabetic patients may contribute to the reduced functionality of pancreatic beta-cells. Sphingolipids 140-152 insulin Homo sapiens 70-77 26380311-2 2015 Many researches indicate lipids, especially the one from the sphingolipids class, as the group of molecules heavily implicated in the progress of insulin resistance in skeletal muscle. Sphingolipids 61-74 insulin Homo sapiens 146-153 25329603-3 2014 Here we have investigated the relationship between the molecular species of sphingolipids in serum and the clinical features of metabolic syndrome, such as obesity, insulin resistance, fatty liver disease and atherogenic dyslipidemia. Sphingolipids 76-89 insulin Homo sapiens 165-172 25305670-1 2014 BACKGROUND: Sphingolipids are increasingly recognized to play a role in insulin resistance and diabetes. Sphingolipids 12-25 insulin Homo sapiens 72-79 25295789-6 2014 Collectively, these studies reveal that altering sphingolipid acylation patterns impacts hepatic steatosis and insulin sensitivity and identify CerS6 as a possible therapeutic target for treating metabolic diseases associated with obesity. Sphingolipids 49-61 insulin Homo sapiens 111-118 23563667-4 2013 Indeed, sphingolipids have been shown to mediate loss of insulin sensitivity, to promote the characteristic diabetic proinflammatory state, and to induce cell death and dysfunction in important organs such as the pancreas and heart. Sphingolipids 8-21 insulin Homo sapiens 57-64 24376889-10 2013 Observed changes in insulin signaling proteins were related to the content of specific sphingolipids, namely to the reduction of ceramide. Sphingolipids 87-100 insulin Homo sapiens 20-27 23250746-3 2013 Ceramides are sphingolipids that modulate a variety of cellular responses including cell death, autophagy, insulin signaling, and inflammation. Sphingolipids 14-27 insulin Homo sapiens 107-114 24749054-2 2014 Among these lipid species, ceramides and more complex sphingolipids have gained recent attention as being pathophysiologically relevant for the development of insulin resistance and impaired glycemic control. Sphingolipids 54-67 insulin Homo sapiens 159-166 24214972-2 2014 Herein we investigated the role of each of these sphingolipids in muscle and adipose tissue and conclude that they are independent and separable antagonists of insulin signaling. Sphingolipids 49-62 insulin Homo sapiens 160-167 29643939-2 2014 Sphingolipids, an important class of structural and signaling lipids, have emerged as key players in the development and pathogenesis of insulin resistance and T2DM. Sphingolipids 0-13 insulin Homo sapiens 137-144 23857140-3 2013 Elevated levels of these sphingolipids in tissues and in the circulation have been associated with insulin resistance and diabetes. Sphingolipids 25-38 insulin Homo sapiens 99-106 23563667-5 2013 Furthermore, plasma sphingolipid levels are emerging as potential biomarkers for the decompensation of insulin resistance to frank type 2 diabetes. Sphingolipids 20-32 insulin Homo sapiens 103-110 22762510-2 2012 Sphingolipids are a class of lipids, which play important roles in cellular biological processes including insulin resistance and myocardial ischemia. Sphingolipids 0-13 insulin Homo sapiens 107-114 22677645-0 2012 Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance. Sphingolipids 0-12 insulin Homo sapiens 78-85 22677645-10 2012 We conclude that the sexual dimorphism in adipose tissue behavior in humans extends to adipose tissue sphingolipid content its association with adiponectin, IL-6 and insulin resistance. Sphingolipids 102-114 insulin Homo sapiens 166-173 22762510-5 2012 Major projects are being realized to develop clinical strategies to manipulate sphingolipid metabolism in this clinical settings, with the ultimate goal of increasing insulin sensitivity and augmenting myocardial tolerance to ischemia. Sphingolipids 79-91 insulin Homo sapiens 167-174 20561942-5 2011 Recent evidence had indicated that increased dietary supply of palmitate can stimulate the rate of sphingolipid synthesis in "lean" tissues and generate excessive amounts of sphingolipid metabolites that have a negative effect on the insulin signaling cascade. Sphingolipids 174-186 insulin Homo sapiens 234-241 21468641-0 2011 Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Sphingolipids 0-13 insulin Homo sapiens 58-65 21468641-8 2011 In light of this, we provide an account of the research investigating how pharmacological inhibition or genetic manipulation of enzymes involved in regulating sphingolipid synthesis can attenuate the insulin-desensitising effects of these obesity-related factors. Sphingolipids 159-171 insulin Homo sapiens 200-207 21910079-2 2011 As sphingolipids have been implicated in the development and pathogenesis of insulin resistance and the metabolic syndrome, it is important to understand their regulation and metabolism. Sphingolipids 3-16 insulin Homo sapiens 77-84 22847494-2 2012 Sphingolipid metabolites such as ceramide, glycosphingolipids, sphingosine 1-phosphate and gangliosides modulate many beta-cell signaling pathways and processes implicated in beta-cell diabetic disease such as apoptosis, beta-cell cytokine secretion, ER-to-golgi vesicular trafficking, islet autoimmunity and insulin gene expression. Sphingolipids 0-12 insulin Homo sapiens 309-316 20561942-6 2011 Many experimental results point to the existence of a causative link between sphingolipid synthesis, insulin response, and hyperglycemia. Sphingolipids 77-89 insulin Homo sapiens 101-108 20937139-0 2010 Sphingolipids: the nexus between Gaucher disease and insulin resistance. Sphingolipids 0-13 insulin Homo sapiens 53-60 20937139-6 2010 Insulin resistance has been reported in patients with Gaucher disease and this article presents evidence that this is due to perturbations in the metabolism of sphingolipids. Sphingolipids 160-173 insulin Homo sapiens 0-7